{
  "questionnaire": {
    "title": "irAKI vs Other AKI Classification Assessment",
    "version": "2.0",
    "timestamp": "Aug 7, 2025",
    "reference": "Sprangers et al. Nature Reviews Nephrology 2022",
    "scale": {
      "type": "9-point Likert",
      "range": "1-9",
      "anchors": {
        "1": "Strongly disagree / Very unlikely",
        "5": "Neutral / Uncertain",
        "9": "Strongly agree / Very likely"
      }
    },
    "questions": [
      {
        "id": "Q1",
        "question": "The temporal relationship between immune checkpoint inhibitor (ICI) exposure and AKI onset strongly supports irAKI diagnosis"
      },
      {
        "id": "Q2",
        "question": "Prerenal causes of AKI have been adequately excluded"
      },
      {
        "id": "Q3",
        "question": "Postrenal/obstructive causes of AKI have been adequately excluded"
      },
      {
        "id": "Q4",
        "question": "Other intrinsic causes of AKI (ATN, contrast nephropathy, other drugs) have been adequately excluded"
      },
      {
        "id": "Q5",
        "question": "Urinalysis findings are consistent with immune-mediated kidney injury"
      }
    ],
    "scoring_guidelines": {
      "interpretation": {
        "1-3": "Evidence strongly against irAKI / Alternative diagnosis likely",
        "4-6": "Uncertain / Requires additional evaluation",
        "7-9": "Evidence strongly supports irAKI / High probability diagnosis"
      },
      "confidence_thresholds": {
        "high_confidence": "≥7 on ≥12 questions with no major contradictions",
        "moderate_confidence": "≥6 on most questions with some uncertainty",
        "low_confidence": "Mixed scores or insufficient evidence"
      }
    }
  }
}